Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016

  • ID: 3720476
  • Drug Pipelines
  • 334 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • GlaxoSmithKline Plc
  • Lipidor AB
  • Pfizer Inc.
  • MORE
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016

Summary

‘Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)
- The report reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Plaque Psoriasis (Psoriasis Vulgaris) therapeutics and enlists all their major and minor projects
- The report assesses Plaque Psoriasis (Psoriasis Vulgaris) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • GlaxoSmithKline Plc
  • Lipidor AB
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Plaque Psoriasis (Psoriasis Vulgaris) Overview

Therapeutics Development

Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) – Overview

Plaque Psoriasis (Psoriasis Vulgaris) – Therapeutics under Development by Companies

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Plaque Psoriasis (Psoriasis Vulgaris) – Products under Development by Companies

Plaque Psoriasis (Psoriasis Vulgaris) – Companies Involved in Therapeutics Development

3SBio Inc.

AbGenomics International, Inc.

Almirall, S.A.

Amgen Inc.

AstraZeneca Plc

Avexxin AS

BIOCAD

Biocon Limited

Bionovis SA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Can-Fite BioPharma Ltd.

Celgene Corporation

Cellceutix Corporation

Celltrion, Inc.

Clonz Biotech Private Limited

Coherus BioSciences, Inc.

Delenex Therapeutics AG

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Forward Pharma A/S

Galectin Therapeutics, Inc.

Genor BioPharma Co., Ltd.

GlaxoSmithKline Plc

Idera Pharmaceuticals, Inc.

Invion Limited

Johnson & Johnson

Kadmon Corporation, LLC

Kineta, Inc.

Kyowa Hakko Kirin Co., Ltd.

LEO Pharma A/S

Lipidor AB

Mabion SA

Maruho Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Momenta Pharmaceuticals, Inc.

Mycenax Biotech Inc.

Novartis AG

Oncobiologics, Inc.

Pfizer Inc.

Promius Pharma, LLC

Protalix BioTherapeutics, Inc.

Provectus Biopharmaceuticals, Inc.

Sandoz International GmbH

Shanghai Celgen Bio-Pharmaceutical Co., Ltd.

Sucampo Pharmaceuticals, Inc.

Sun Pharma Advanced Research Company Ltd.

Takeda Pharmaceutical Company Limited

TetraLogic Pharmaceuticals

Therapeutic Proteins International, LLC

UCB S.A.

Valeant Pharmaceuticals International, Inc.

XBiotech USA, Inc.

Ziarco Pharma Ltd

Plaque Psoriasis (Psoriasis Vulgaris) – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(betamethasone dipropionate + calcipotriene) - Drug Profile

(betamethasone valerate + calcipotriene) - Drug Profile

(halobetasol propionate + tazarotene) - Drug Profile

AbGn-168H - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

AM-001 - Drug Profile

amiselimod hydrochloride - Drug Profile

AVX-001 - Drug Profile

baricitinib - Drug Profile

bimekizumab - Drug Profile

bleselumab - Drug Profile

BMS-986165 - Drug Profile

brodalumab - Drug Profile

BTX-1308 - Drug Profile

C-82 - Drug Profile

calcipotriene - Drug Profile

CC-90005 - Drug Profile

certolizumab pegol - Drug Profile

CJM-112 - Drug Profile

dalazatide - Drug Profile

DFD-01 - Drug Profile

DFD-06 - Drug Profile

dimethyl fumarate - Drug Profile

dimethyl fumarate - Drug Profile

DLX-105 - Drug Profile

DNX-114 - Drug Profile

etanercept - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

GK-664S - Drug Profile

GRMD-02 - Drug Profile

GSK-2831781 - Drug Profile

GSK-2981278 - Drug Profile

guselkumab - Drug Profile

IDP-122 - Drug Profile

IMO-8400 - Drug Profile

IMP-731 - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

INV-103 - Drug Profile

ixekizumab - Drug Profile

KD-025 - Drug Profile

KM-133 - Drug Profile

LEO-32731 - Drug Profile

LP-0113 - Drug Profile

M-7040 - Drug Profile

MC-201 - Drug Profile

namilumab - Drug Profile

pefcalcitol - Drug Profile

PF-06700841 - Drug Profile

PH-10 - Drug Profile

piclidenoson - Drug Profile

RA-18C3 - Drug Profile

remetinostat - Drug Profile

risankizumab - Drug Profile

RTU-1096 - Drug Profile

seletalisib - Drug Profile

tildrakizumab - Drug Profile

tofacitinib - Drug Profile

toreforant tartrate - Drug Profile

ustekinumab biosimilar - Drug Profile

ustekinumab biosimilar - Drug Profile

ustekinumab biosimilar - Drug Profile

ZPL-3893787 - Drug Profile

Plaque Psoriasis (Psoriasis Vulgaris) – Recent Pipeline Updates

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects

Plaque Psoriasis (Psoriasis Vulgaris) – Discontinued Products

Plaque Psoriasis (Psoriasis Vulgaris) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by 3SBio Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by AbGenomics International, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Almirall, S.A., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Amgen Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by AstraZeneca Plc, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Avexxin AS, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by BIOCAD, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Biocon Limited, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Bionovis SA, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Boehringer Ingelheim GmbH, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Bristol-Myers Squibb Company, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Can-Fite BioPharma Ltd., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Celgene Corporation, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Cellceutix Corporation, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Celltrion, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Clonz Biotech Private Limited, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Coherus BioSciences, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Delenex Therapeutics AG, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Eli Lilly and Company, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Forward Pharma A/S, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Galectin Therapeutics, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Genor BioPharma Co., Ltd., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by GlaxoSmithKline Plc, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Idera Pharmaceuticals, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Invion Limited, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Johnson & Johnson, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Kadmon Corporation, LLC, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Kineta, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by LEO Pharma A/S, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Lipidor AB, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Mabion SA, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Maruho Co., Ltd., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Momenta Pharmaceuticals, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Mycenax Biotech Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Novartis AG, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Oncobiologics, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Pfizer Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Promius Pharma, LLC, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Protalix BioTherapeutics, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Sandoz International GmbH, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by TetraLogic Pharmaceuticals, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Therapeutic Proteins International, LLC, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by UCB S.A., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by XBiotech USA, Inc., H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline by Ziarco Pharma Ltd, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics – Recent Pipeline Updates, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Dormant Projects, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Dormant Projects (Contd..1), H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Dormant Projects (Contd..2), H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Dormant Projects (Contd..3), H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Dormant Projects (Contd..4), H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Dormant Projects (Contd..5), H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Dormant Projects (Contd..6), H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Discontinued Products, H1 2016

Plaque Psoriasis (Psoriasis Vulgaris) – Discontinued Products (Contd..1), H1 2016

List of Figures

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
3SBio Inc.
AbGenomics International, Inc.
Almirall, S.A.
Amgen Inc.
AstraZeneca Plc
Avexxin AS
BIOCAD
Biocon Limited
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Celgene Corporation
Cellceutix Corporation
Celltrion, Inc.
Clonz Biotech Private Limited
Coherus BioSciences, Inc.
Delenex Therapeutics AG
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Forward Pharma A/S
Galectin Therapeutics, Inc.
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
Idera Pharmaceuticals, Inc.
Invion Limited
Johnson & Johnson
Kadmon Corporation, LLC
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
LEO Pharma A/S
Lipidor AB
Mabion SA
Maruho Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Novartis AG
Oncobiologics, Inc.
Pfizer Inc.
Promius Pharma, LLC
Protalix BioTherapeutics, Inc.
Provectus Biopharmaceuticals, Inc.
Sandoz International GmbH
Shanghai Celgen Bio-Pharmaceutical Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
Takeda Pharmaceutical Company Limited
TetraLogic Pharmaceuticals
Therapeutic Proteins International, LLC
UCB S.A.
Valeant Pharmaceuticals International, Inc.
XBiotech USA, Inc.
Ziarco Pharma Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll